News | Pharmaceuticals | February 07, 2017

GE Healthcare to Commercialize Rapiscan Agent Outside North America

Availability of Rapiscan worldwide will provide imaging for coronary artery disease in larger adult patient populations

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.

February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan (regadenoson) in territories outside the U.S., Canada and Mexico. GE Healthcare will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.

Rapiscan is a European Medicines Agency (EMA)-approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease, accounting for over 680,000 deaths in Europe alone[1] .

While MPIs are most commonly performed after a patient has exercised, some patients at risk of CAD cannot exercise due to various conditions such as asthma and chronic obstructive pulmonary disease. Rapiscan reduces the risks[2] of MPI tests for these patients by stimulating a patient’s heart to bring on the effects of exercise.

GE Healthcare already distributes Rapiscan in the U.K. and Germany and will maintain existing supplier and distributor networks created by Rapidscan Pharma Solutions to expand its global reach. Its commercial rights will complement Astellas’ commercial distribution of regadenoson in the U.S., Canada, and Mexico.

For more information: www.gehealthcare.com

References

[1] European Society of Cardiology. European Cardiovascular Disease Statistics, 2012. https://www.escardio.org/static_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf

[2] Cerqueira MD et al, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008; 1: 307-316.

[3] Rapidscan.Rapiscan: Information Memorandum. 2016; 4

Related Content

A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Cardiac Imaging | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve).

At #ACC.19, Siemens unveiled a version of its go.Top platform optimized for cardiovascular imaging. The newly packaged scanner can generate the data needed to do CT-based FFR (fractional flow reserve). Photo by Greg Freiherr

Feature | Cardiac Imaging | March 22, 2019 | By Greg Freiherr
Reflecting a trend toward the increased use of ...
SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram.

SyncVision iFR Co-registration from Philips Healthcare maps iFR pressure readings onto angiogram. Results from an international study presented at #ACC19 show that pressure readings in coronary arteries may identify locations of stenoses remaining after cardiac cath interventions.

Feature | Cardiac Imaging | March 18, 2019 | By Greg Freiherr
As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the
Jennifer N. A. Silva, M.D., a pediatric cardiologist at Washington University School of Medicine in Saint Louis, Mo., describes “mixed reality” at ACC19 Future Hub.

Jennifer N. A. Silva, M.D., a pediatric cardiologist at Washington University School of Medicine in Saint Louis, Mo., describes “mixed reality” at ACC19 Future Hub.

Feature | Cardiac Imaging | March 17, 2019 | By Greg Freiherr
Virtual reality (VR) and its less immersive kin, augmented reality (AR), are gaining traction in some medical applica
WVU cardiology chief Partho Sengupta, M.D., describes at ACC 2019 how artificial intelligence already helps cardiologists in echocardiography.

WVU cardiology chief Partho Sengupta, M.D., describes at ACC 2019 how artificial intelligence already helps cardiologists in echocardiography. Photo by Greg Freiherr

Feature | Cardiac Imaging | March 16, 2019 | By Greg Freiherr
Machine learning is already having an enormous impact on cardiology, automatically calculating measurements in echoca
Podcast | Cardiac Imaging | March 15, 2019
Debate About Coronary Testing Highlights ACC Session

Collage depicts broad applications in machine learning or deep learning (DL) that can be applied to advanced medical imaging technologies. Size of the liver and its fat fraction — 22 percent — (top middle in collage) can be quantified automatically using an algorithm developed by Dr. Albert Hsiao and his team at the University of California San Diego. This and other information that might be mined by DL algorithms from CT and MR images could help personalize patients’ treatment. Collage provided by Albert Hsiao

Feature | Cardiac Imaging | March 12, 2019 | By Greg Freiherr
Acquiring these data could change patient management
Podcast | Cardiac Imaging | March 12, 2019
How smart algorithms might reduce the burden of modern practice
Podcast | Cardiac Imaging | March 08, 2019
Why CT angiography cannot replace invasive angiography
Podcast | Cardiac Imaging | March 04, 2019
AI, Mobile Technologies Are Changing How We Think About Cardiac Disease
Overlay Init